Sun Pharma’s Q3 net profit grew 15% YoY to Rs 2,903 crore, driven by strong sales in India and emerging markets. Revenue rose to Rs 13,675 crore, up 10% YoY. The company declared an interim dividend of Rs 10.5 per share, higher than last year’s Rs 8.50. India sales grew 13.8%, while US sales dipped marginally. The stock closed 0.12% lower at Rs 1,743.10.
